<DOC>
	<DOCNO>NCT00652184</DOCNO>
	<brief_summary>A multi-center , randomize , 4-arm , placebo-controlled , double-blind efficacy study ARYS-01 ( sorivudine ) cream 3 % .</brief_summary>
	<brief_title>Study Compare Efficacy Topical ARYS-01 ( Sorivudine ) Cream 3 % , Oral Valaciclovir Combination ARYS-01 Cream 3 % /Oral Valaciclovir Treatment Herpes Zoster ( Shingles )</brief_title>
	<detailed_description>More 95 % people infected varicella Zoster virus ( VZV ) one time life another . Primary VZV infection manifest varicella ( chicken pox ) . The virus establish latent infection sensory ganglion may reactivate year later produce clinical syndrome Herpes Zoster ( shingle ) . The initial cutaneous VZV lesion pruritic , erythematous macule ; lesion progress maculopapular stage vesicular , ulceration crusting phase . The crust phase signal begin heal process , begin cloud vesicular fluid , within 24 48 h appearance lesion . This Phase 2 study ass : 1 ) overall benefit ARYS-01 ( sorivudine ) cream 3 % v . Placebo cream ( immediate delay use Valaciclovir therapy ) Herpes Zoster rash heal rate postherpetic neuralgia ( PHN ) , 2 ) efficacy ARYS-01 cream 3 % v . Placebo cream , prior initiation Valaciclovir , build evidence monotherapy treatment benefit ARYS-01 cream initial onset Herpes Zoster symptom , 3 ) efficacy ARYS-01 cream 3 % v . Placebo cream , immediate delay initiation Valaciclovir , synergetic effect initial onset Herpes Zoster symptom . The primary efficacy endpoint effect ARYS-01 cream ( without Valaciclovir ) reduction crust stage VZV rash present Day 8 . Secondary endpoint include time cessation new lesion formation , time cessation Zoster-associated pain , pain intensity , rash heal size reduction , lesion dissemination .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Sorivudine</mesh_term>
	<criteria>least 18 year age diagnose herpes zoster confirm VZV lesion swab screen subsequent PCR test . contraception woman childbearing potential able communicate investigator compliant cytotoxic immunosuppressive drug within 3 mo , 5FU prodrugs , tricyclic antidepressant , probenecid , topical systemic antiviral drug immunomodulatory agent viral infection herpes zoster ophthalmicus female patient pregnant and/or nursing planning pregnancy congenital , acquire corticosteroidinduced immunodeficiency , include malignancy renal insufficiency creatinine level &gt; 2mg/dL clinical significant liver enzyme abnormality laboratory abnormality determine screen lab history intolerance hypersensitivity cream component current significant skin disease within affected dermatome history positive result hepatitis B surface antigen , hepatitis C virus , HIV current participation another clinical drug research study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>antiviral</keyword>
	<keyword>herpes zoster</keyword>
	<keyword>postherpetic neuralgia</keyword>
	<keyword>varicella zoster virus</keyword>
	<keyword>shingle</keyword>
</DOC>